Rituximab may help patients with aPL-related clinical problemsNews-Medical.netRituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not resp…
Rituximab shows promise for clinical problems tied to antiphospholipid antibodiesScience CodexRituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems …
Multiple Sclerosis 'immune Exchange' Between Brain and Blood Is UncoveredScience Daily (press release)These trials used Rituximab and Ocrelizumab, both of which target a molecule called CD20 found on the surface of B cells. The new work suggest…
Musculoskeletal Network Launches Special Coverage of FDA Biosimilars PolicyMelodika.net (press release)Many newer "biological" drugs currently approved for these disorders, such as adalimumab (Humira) and rituximab (Rituxan), are identical to…
Drug Combo Offers Long-Term Benefits in SLEMedPage TodayWASHINGTON — An 18-month treatment with the combination of rituximab and cyclophosphamide (Cytoxan) stopped progression of systemic lupus erythematosus (SLE) for at least 3 years, researchers her…
Immunotherapeutic Approaches Have the Potential to Brighten the Future Not …Cancer NetworkAs critically discussed by the authors, a multitude of previous trials and currently available treatment regimens, including rituximab-based chemo-immunotherapy…
5 Drug Hopefuls That Are Going to Change Your Life: Part 1Motley FoolIt currently has a partnership with Abbott Labs (NYSE: ABT ) and is in the middle of a late-stage MS trial for daclizumab, a subcutaneous injection for relapsing and remitting MS . Mo…
SEP : un engagement, des résultats !JIM.frIl nous a aussi informé de l'existence d'autres produits en cours d'investigation dans la sclérose en plaques : un anticorps monoclonal anti-CD 25 (daclizumab), un interféron pegylé et un anti-…
Is the show over for CYC in ANCA-associated vasculitis?Rheumatology UpdateWASHINGTON: Cyclophosphamide continues to have a role in ANCA-associated vasculitis but rituximab can be considered a valid option for newly diagnosed patients with severe diseas…
Rituxan Turns in Good Safety Profile in RAMedPage TodayWASHINGTON — Serious infectious events associated with rituximab (Rituxan) remain consistently low in rheumatoid arthritis (RA) patients for nearly a decade after first treatment, researchers said…